-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter

Equities analysts expect that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will post ($0.06) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at ($0.05). AVEO Pharmaceuticals posted earnings per share of ($0.02) in the same quarter last year, which suggests a negative year over year growth rate of 200%. The company is expected to issue its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full-year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($0.20) to ($0.12). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.61) to ($0.14). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.09). The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.35 million.

Several equities research analysts have recently commented on AVEO shares. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 11th. HC Wainwright started coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, August 16th. They issued a “buy” rating and a $6.50 target price on the stock. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. AVEO Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $5.50.

Shares of NASDAQ:AVEO traded up $0.10 on Monday, hitting $2.70. The stock had a trading volume of 3,202,026 shares, compared to its average volume of 2,098,986. AVEO Pharmaceuticals has a twelve month low of $1.86 and a twelve month high of $3.69. The company has a debt-to-equity ratio of -0.36, a quick ratio of 1.16 and a current ratio of 1.16. The company has a market capitalization of $393.99 million, a PE ratio of -16.88 and a beta of 1.67.

In other news, major shareholder Equity Opportunities Iv Growth bought 250,600 shares of AVEO Pharmaceuticals stock in a transaction dated Thursday, July 19th. The shares were bought at an average price of $1.96 per share, for a total transaction of $491,176.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 4.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp lifted its position in AVEO Pharmaceuticals by 396.0% during the 2nd quarter. Northern Trust Corp now owns 1,098,075 shares of the biopharmaceutical company’s stock worth $2,482,000 after buying an additional 876,703 shares in the last quarter. Bank of New York Mellon Corp lifted its position in AVEO Pharmaceuticals by 279.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 288,073 shares of the biopharmaceutical company’s stock worth $651,000 after buying an additional 212,059 shares in the last quarter. Granahan Investment Management Inc. MA lifted its position in AVEO Pharmaceuticals by 16.3% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 179,512 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 25,134 shares in the last quarter. BlackRock Inc. lifted its position in AVEO Pharmaceuticals by 271.9% during the 2nd quarter. BlackRock Inc. now owns 6,977,746 shares of the biopharmaceutical company’s stock worth $15,770,000 after buying an additional 5,101,281 shares in the last quarter. Finally, NEA Management Company LLC lifted its position in AVEO Pharmaceuticals by 8.7% during the 2nd quarter. NEA Management Company LLC now owns 17,783,722 shares of the biopharmaceutical company’s stock worth $40,091,000 after buying an additional 1,421,028 shares in the last quarter. Institutional investors and hedge funds own 50.53% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Read More: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply